FDC India

FDC.NSPre-clinical

FDC Limited is a prominent Indian pharmaceutical player with a legacy dating back to 1936, focusing on developing, manufacturing, and marketing a wide range of pharmaceutical formulations. The company has established a robust commercial footprint in India and over 50 other countries, leveraging its expertise in branded generics and OTC segments. Its strategic direction emphasizes portfolio expansion in chronic therapies, geographical diversification, and strengthening its API vertical to ensure cost competitiveness and supply chain resilience.

Market Cap

$579.2M

Employees

2000-5000

Focus

Biotech

FDC.NS · Stock Price

USD 333.15+74.75 (+28.93%)

Historical price data

AI Company Overview

Technology Platform

Focus on formulation development, novel drug delivery systems (NDDS), and manufacturing process innovation for generic pharmaceuticals and active pharmaceutical ingredients (APIs).

Funding History

IPOUndisclosedUndisclosedJun 15, 1994

Opportunities

Growth is driven by expansion in chronic therapy segments, geographic diversification into emerging international markets, and leveraging government incentives for API manufacturing.

The strong OTC brand portfolio is well-positioned to capitalize on increasing self-medication trends.

Risk Factors

Key risks include stringent price controls in the domestic market, regulatory compliance challenges for manufacturing facilities, volatility in raw material costs, and intense competition eroding market share and margins.

Competitive Landscape

FDC competes with large Indian generics firms like Sun Pharma and Cipla, as well as OTC giants. Its differentiation lies in strong brand loyalty in specific therapeutic niches (e.g., Electral for ORS), a deep distribution network in India, and a vertically integrated model with API capabilities.

Publications